150 related articles for article (PubMed ID: 2974204)
1. An overview of the use of the monoclonal antibody OKT3 in renal transplantation.
Norman DJ
Transplant Proc; 1988 Dec; 20(6):1248-52. PubMed ID: 2974204
[TBL] [Abstract][Full Text] [Related]
2. Immunologic monitoring with Orthoclone OKT3 therapy.
Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
[TBL] [Abstract][Full Text] [Related]
3. The clinical role of OKT3.
Norman DJ
Cardiol Clin; 1990 Feb; 8(1):97-105. PubMed ID: 2407364
[TBL] [Abstract][Full Text] [Related]
4. Reactivity of patient antisera to OKT3 with a panel of CD3 monoclonal antibodies.
Nashan B; Schwinzer R; Wonigeit K; Pichlmayr R
Transplant Proc; 1989 Feb; 21(1 Pt 1):985-6. PubMed ID: 2523157
[No Abstract] [Full Text] [Related]
5. The human antimouse reaction to OKT3: cross-reactive pattern analysis using a large group of anti-CD3 and isotypic monoclonal antibodies.
Shield CF; Hughes JD; Marlett P; Norman DJ
Transplant Proc; 1989 Feb; 21(1 Pt 1):981-4. PubMed ID: 2523156
[No Abstract] [Full Text] [Related]
6. Acute toxicity of anti-CD3 monoclonal antibody in mice: a model for OKT3 first dose reactions.
Alegre M; Depierreux M; Florquin S; Najdovski T; Vandenabeele P; Abramowicz D; Leo O; Deschodt-Lanckman M; Goldman M
Transplant Proc; 1990 Aug; 22(4):1920-1. PubMed ID: 2143864
[No Abstract] [Full Text] [Related]
7. RIV-9: a mouse IgG3 anti-human CD3 monoclonal antibody with strong antigen modulating and T cell eliminating properties.
Vaessen LM; Kreeftenberg JG; Heyse P; Leerling MF; Baumgartner D; Hendriks GF; Jutte NH; Weimer W
Transplant Proc; 1989 Feb; 21(1 Pt 1):1026-7. PubMed ID: 2523112
[No Abstract] [Full Text] [Related]
8. Acute cellular rejection during effective early prophylactic OKT3 monoclonal antibody treatment after renal transplantation.
Haak HH; Weening JJ; Rischen-Vos J; Daha MR; van Es LA; van der Woude FJ
Transplantation; 1989 Aug; 48(2):352-4. PubMed ID: 2526973
[No Abstract] [Full Text] [Related]
9. Are OKT3 binding sites on T cells modulated or merely converted (blindfolded) by OKT3 during therapy?
Carreno M; Miller J; Esquenazi V; Milgrom M; Roth D; Fuller L
Transplant Proc; 1989 Feb; 21(1 Pt 1):987-8. PubMed ID: 2565060
[No Abstract] [Full Text] [Related]
10. Fine-needle aspiration cytology during treatment with orthoclone monoclonal antibody OKT3 for acute cellular rejection after renal transplantation.
Hansen BL; Foged N; Nielsen E; Elbirk A; Rohr N; Svendsen V; Birkeland SA
Transplant Proc; 1988 Aug; 20(4):626-8. PubMed ID: 2970142
[No Abstract] [Full Text] [Related]
11. The OKT3 immunosuppressive effect. In situ antigenic modulation of human graft-infiltrating T cells.
Caillat-Zucman S; Blumenfeld N; Legendre C; Noel LH; Bach JF; Kreis H; Chatenoud L
Transplantation; 1990 Jan; 49(1):156-60. PubMed ID: 2137271
[TBL] [Abstract][Full Text] [Related]
12. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses.
Norman DJ; Barry JM; Bennett WM; Munson JL; Meyer M; Henell K; Kimball J; Hubert B
Transplant Proc; 1991 Feb; 23(1 Pt 2):1052-4. PubMed ID: 1846453
[No Abstract] [Full Text] [Related]
13. The use of an anti-CD3 priming dose to enhance the immunosuppressive potency of monoclonal and polyclonal T-cell antisera.
Sherburne CG; Onyekaba CO; Condie RM
Transplant Proc; 1991 Feb; 23(1 Pt 1):626-9. PubMed ID: 1824996
[No Abstract] [Full Text] [Related]
14. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection.
Waid TH; Lucas BA; Amlot P; Janossy G; Yacoub M; Cammisuli S; Jezek D; Rhoades J; Brown S; Thompson JS
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):61-70. PubMed ID: 2479265
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of interleukin 6 during OKT3 treatment in renal allograft recipients.
Bloemena E; ten Berge IJ; Surachno J; Wilmink JM
Transplantation; 1990 Aug; 50(2):330-1. PubMed ID: 2143327
[No Abstract] [Full Text] [Related]
16. Advantages of F(ab')2 fragments of anti-CD3 monoclonal antibody as compared to whole antibody as immunosuppressive agents in mice.
Hirsch R; Bluestone JA; Bare CV; Gress RE
Transplant Proc; 1991 Feb; 23(1 Pt 1):270-1. PubMed ID: 1824981
[No Abstract] [Full Text] [Related]
17. Reversible pancytopenia following OKT3. Use in the context of multidrug immunosuppression for kidney allografting.
Burke GW; Vercellotti GM; Simmons RL; Howe RB; Canafax DM; Najarian JS
Transplantation; 1989 Sep; 48(3):403-8. PubMed ID: 2528849
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic use of anti-CD3 monoclonal antibody WT32 in kidney transplantation.
Frenken LA; Hoitsma AJ; Tax WJ; Koene RA
Transplant Proc; 1991 Feb; 23(1 Pt 2):1072-3. PubMed ID: 1824887
[No Abstract] [Full Text] [Related]
19. Usefulness of CD3 or CD6 anti-T monoclonal antibodies in the treatment of acute corneal graft rejection.
Ippoliti G; Fronterrè A
Transplant Proc; 1989 Feb; 21(1 Pt 3):3133-4. PubMed ID: 2523173
[No Abstract] [Full Text] [Related]
20. The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506.
Li PK; Nicholls MG; Lai KN
Adverse Drug React Acute Poisoning Rev; 1990; 9(3):123-55. PubMed ID: 1703724
[No Abstract] [Full Text] [Related]
[Next] [New Search]
